Arctic Bioscience is set to share an operational update for the fourth quarter of 2025 this Thursday, February 26, 2026, at 7:00 AM Central European Time (CET). The company will follow up with a webcast presentation at 10:00 AM CET the same day, offering a deeper dive into the results and opening the floor for questions from attendees. This announcement regarding the Q4 2025 operational update is considered legally mandated information disclosure under the Norwegian Securities Trading Act § 5-12.
The webcast will be conducted in both Norwegian and English, making the information accessible to a wider audience of investors and stakeholders. Participants can access the presentation via a Microsoft Teams link: https://events.teams.microsoft.com/event/14063048-ef68-47fa-a928-7b6060c7ee61@ce618813-5158-40b5-b6d0-2f2cd3f39b20. Arctic Bioscience, a biotechnology company focused on developing and commercializing pharmaceutical products and dietary supplements based on unique bioactive marine raw materials, has been steadily advancing its pipeline and market presence.
Developing Treatments for Psoriasis
A key focus for Arctic Bioscience is the development of HRO350, a novel oral drug candidate currently in development for the treatment of mild-to-moderate psoriasis. The company highlights the significant necessitate for new, effective psoriasis treatments with a favorable safety profile, suggesting a substantial potential market for HRO350. Psoriasis is a chronic autoimmune disease that affects the skin, causing inflammation and scaling. The development of new treatments aims to improve the quality of life for the millions affected by this condition.
ROMEGA® and Global Dietary Supplement Sales
Beyond pharmaceutical development, Arctic Bioscience also generates revenue through its line of dietary supplements sold under the ROMEGA® brand. These supplements, derived from unique marine raw materials, are marketed globally both as bulk ingredients for other manufacturers and as finished products directly to consumers. The company’s diversified approach, encompassing both pharmaceutical innovation and established dietary supplement sales, positions it for continued growth and stability.
Leadership and Expertise
Arctic Bioscience is led by a team with diverse and relevant experience, according to the company. CEO Christer L. Valderhaug can be reached at [email protected] (+47 920 84 601), although CFO Jone R. Slinning is available at [email protected] (+47 948 75 469). This experienced leadership team is guiding the company through its development phases and commercialization efforts.
Financial Calendar and Future Updates
Looking ahead, Arctic Bioscience has outlined its financial reporting schedule. According to the financial calendar on the company’s website, the release of the 2025 Annual Report is scheduled for May 7, 2026, followed by the Annual General Meeting on May 27, 2026. The half-year report for 2026 is expected on August 27, 2026. The company publishes financial reports only for half-year and full-year periods.
The company’s commitment to transparency and regular updates is evident in its publicly available financial calendar. Investors and interested parties can stay informed about Arctic Bioscience’s progress through these scheduled reports and presentations. The upcoming Q4 2025 operational update webcast provides another opportunity to gain insights into the company’s performance and future plans.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Investing in biotechnology companies involves risks, and readers should conduct their own due diligence before making any investment decisions.
The next key date for Arctic Bioscience is the release of its 2025 Annual Report on May 7, 2026. Stay tuned for further updates as the company continues to advance its innovative pipeline and expand its market reach. What are your thoughts on Arctic Bioscience’s potential? Share your comments below and let us know.
